$0.88
(Market cap
$1,873 Mln
Recently Viewed
Clear AllMarket cap
$1,873 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.9
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
65,407,822
CFO
€-235.00 Mln
EBITDA
€-284.39 Mln
Net Profit
€-256.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pharvaris BV (PHVS)
| 10.6 | 12.3 | 10.2 | 77.8 | 48.6 | 4.3 | -- |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
|---|---|---|---|
|
Pharvaris BV (PHVS)
| 44.8 | 149.3 | -21.8 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pharvaris BV (PHVS)
|
30.7 | 1,872.6 | 0.0 | -176.1 | -- | -60.4 | -- | 5.9 |
| 0.1 | 3.0 | 0.9 | -70.0 | -7,823.0 | -241.9 | -- | 0.1 | |
| 0.1 | 9.4 | 48.5 | -35.5 | -117.5 | 397.6 | -- | 0.9 | |
| 4.7 | 1,049.3 | 510.5 | 193.6 | -21.7 | 25.5 | 7 | 1.0 | |
| 1.9 | 107.0 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 2.2 | |
| 1.7 | 45.8 | 5.0 | -23.3 | -442.3 | -121 | -- | 3.6 | |
| 1.6 | 163.3 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 3.0 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a... small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland. Read more
Co-Founder, CEO & Executive Director
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Co-Founder, CEO & Executive Director
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Headquarters
Zug
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Pharvaris BV (PHVS) is $30.71 (NASDAQ) as of 30-Apr-2026 11:38 EDT. Pharvaris BV (PHVS) has given a return of 48.64% in the last 3 years.
Since, TTM earnings of Pharvaris BV (PHVS) is negative, P/E ratio is not available.
The P/B ratio of Pharvaris BV (PHVS) is 5.90 times as on 24-Apr-2026, a 4 premium to its peers’ median range of 5.67 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-9.32
|
6.04
|
|
2024
|
-7.71
|
3.87
|
|
2023
|
-10.57
|
2.78
|
|
2022
|
-5.01
|
2.56
|
|
2021
|
-10.10
|
2.11
|
The 52-week high and low of Pharvaris BV (PHVS) are Rs 30.71 and Rs 14.59 as of 30-Apr-2026.
Pharvaris BV (PHVS) has a market capitalisation of $ 1,873 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Pharvaris BV (PHVS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.